Market Place
Sourcing Support
Jury convicts 2 former biopharma leaders of fraud
10 Dec 2024 //
FIERCE BIOTECH
CytoDyn Appoints Richard Pestell as Oncology Lead Consultant
25 Nov 2024 //
GLOBENEWSWIRE
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
04 Nov 2024 //
GLOBENEWSWIRE
CytoDyn Appoints Dr. Melissa Palmer as Hepatology Consultant
30 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Appoints Dr. Lataillade As Head Of Clinical Development
08 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Announces Abstract On Leronlimab`s Potential
07 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Engages Syneos Health For Phase II Oncology Trial
04 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Announces Preliminary Findings in Study with SMC Lab
24 Sep 2024 //
GLOBENEWSWIRE
September 2024 Letter to Shareholders
09 Sep 2024 //
GLOBENEWSWIRE
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
23 Aug 2024 //
GLOBENEWSWIRE
CytoDyn Completes FDA Meeting On Leronlimab Colorectal Cancer Study
12 Aug 2024 //
GLOBENEWSWIRE
CytoDyn Announces Settlement with Amarex Clinical Research LLC
09 Jul 2024 //
GLOBENEWSWIRE
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
27 Jun 2024 //
GLOBENEWSWIRE
CytoDyn to Host Webcast to Provide Company Update
28 May 2024 //
GLOBENEWSWIRE
CytoDyn Announces FDA Has Lifted Clinical Hold
29 Feb 2024 //
GLOBENEWSWIRE
CytoDyn finally clears FDA hold on HIV program after two years
29 Feb 2024 //
FIERCE BIOTECH
CytoDyn Announces Initiation of Pre-Clinical Study in Glioblastoma
01 Feb 2024 //
GLOBENEWSWIRE
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
29 Jan 2024 //
GLOBENEWSWIRE
CytoDyn Announces Webcast to Provide Company Update
07 Dec 2023 //
GLOBENEWSWIRE
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
21 Nov 2023 //
GLOBENEWSWIRE
November 2023 Letter to Shareholders
03 Nov 2023 //
GLOBENEWSWIRE
CytoDyn Announces Company Updates and Investment Community Update Webcast
11 Jul 2023 //
GLOBENEWSWIRE
CytoDyn Announces President Takes Medical Leave of Absence
24 May 2023 //
GLOBENEWSWIRE
CytoDyn to Hold Webcast to Provide a Company Update
05 Apr 2023 //
GLOBENEWSWIRE
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Trials
23 Dec 2022 //
GLOBENEWSWIRE
Ex-CytoDyn CEO, Amarex CEO hit with multiple fraud charges
21 Dec 2022 //
FIERCEBIOTECH
Facing decades in prison, two biotech leaders charged wire & securities fraud
21 Dec 2022 //
ENDPTS
Two biotech CEOs charged with defrauding investors
21 Dec 2022 //
UPI
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
22 Nov 2022 //
GLOBENEWSWIRE
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data issue
29 Oct 2022 //
PRESS RELEASE
CytoDyn Announces Appointment of Additional Directors with Industry Experience
20 Oct 2022 //
GLOBENEWSWIRE
Under new leadership, CytoDyn ditches COVID-19 programs
29 Sep 2022 //
FIERCEBIOTECH
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President
13 Jul 2022 //
GLOBENEWSWIRE
CytoDyn Highlights NIH Grant for HIV Functional Cure PC Study of Leronlimab
11 Jul 2022 //
GLOBENEWSWIRE
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
22 Jun 2022 //
GLOBENEWSWIRE
CytoDyn Announces Resolution of Legal Dispute with Former CMO
23 May 2022 //
GLOBENEWSWIRE
CytoDyn Announces Addition of Leading Experts in Scientific Board of Advisors
13 May 2022 //
GLOBENEWSWIRE
CytoDyn Suppresses Human and Simian Immunodeficiency Virus Replication
12 Apr 2022 //
GLOBENEWSWIRE
CytoDyn`s leronlimab slapped with FDA holds in COVID, HIV
31 Mar 2022 //
FIERCEBIOTECH
CytoDyn to Hold Webcast to Provide Company Update
30 Mar 2022 //
GLOBENEWSWIRE
FDA slams former CytoDyn CEO`s misleading interview in new warning letter
23 Feb 2022 //
ENDPTS
CytoDyn, Inc Receives FDA Warning Letter
23 Feb 2022 //
FDA
CytoDyn fires embattled CEO as its growing chorus of critics gets louder
27 Jan 2022 //
ENDPTS
Regnum Signs Agreement with CytoDyn, SevenScore to Commercialize Leronlimab
10 Jan 2022 //
PRNEWSWIRE
Leronlimab 14-Week, NASH Clinical Trial Met Primary and Secondary Endpoint
05 Jan 2022 //
BUSINESSWIRE
CytoDyn Submits Protocol with FDA for Phase 3 Registrational Trial of Leronlimab
09 Dec 2021 //
BUSINESSWIRE
CytoDyn Files for Expanded Access Use of Leronlimab
09 Dec 2021 //
BUSINESSWIRE
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill
08 Dec 2021 //
BUSINESSWIRE
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA
01 Dec 2021 //
BIOSPACE
Health Canada Grants EUA to Leronlimab for TNBC Patients in Canada
16 Nov 2021 //
BUSINESSWIRE
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA
16 Nov 2021 //
GLOBENEWSWIRE
CytoDyn Submits Breakthrough Therapy Designation Application to FDA Leronlimab
08 Nov 2021 //
GLOBENEWSWIRE
Fierce Biotech’s Rotten Tomatoes 2021
08 Nov 2021 //
FIERCEBIOTECH
CytoDyn Reports Prelim Results from Phase 2 NASH Open Label Leronlimab Trial
03 Nov 2021 //
GLOBENEWSWIRE
CytoDyn knowingly submitted incomplete drug application, new documents show
28 Oct 2021 //
STATNEWS
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for BLA
27 Oct 2021 //
GLOBENEWSWIRE
CytoDyn treats first subject in Phase III Covid-19 trial of leronlimab
25 Oct 2021 //
CLINICALTRIALSARENA
CytoDyn Announces Treatment of First Patient in Pivotal Phase 3
25 Oct 2021 //
GLOBENEWSWIRE
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
14 Oct 2021 //
CYTODYN
ANVISA Clears CytoDyn`s Phase 3 Trial in Critically Ill COVID-19 Patients
22 Sep 2021 //
BIOSPACE
